前列腺癌放疗后骨盆骨髓剂量与血红蛋白水平降低的剂量学相关性
该研究基于2008至2021年前列腺癌前瞻性机构数据库,分析203例接受根治性放疗患者骨盆骨髓剂量与贫血的相关性。骨盆骨髓接受≥15 Gy体积>1000 cc者第90天预测血红蛋白显著低于≤1000 cc者(12.8 g/dL vs 14.5 g/dL,P<.05)。重新优化20例计划可将接受15 Gy的骨髓体积从1422 cc降至997 cc而不影响靶区覆盖。
要点
- 骨盆骨髓接受≥15 Gy体积>1000 cc者第90天预测血红蛋白显著低于≤1000 cc者。
- 归一化基线血红蛋白后,高体积组第90天仍显著低于低体积组(86.1% vs 96.2%)。
- 重新优化20例计划可将接受15 Gy的骨髓体积均值从1422 cc降至997 cc,未影响危及器官或靶区覆盖。
核心结论
- 骨盆骨髓接受≥15 Gy体积>1000 cc的患者第90天预测血红蛋白水平显著低于≤1000 cc者。
- 重新优化计划证明该剂量约束可实现且不损害计划质量,可考虑用于限制前列腺癌患者急性骨髓毒性。
研究设计与样本
- 研究为基于2008至2021年前瞻性机构数据库的患者选择分析,最终纳入203例接受根治性放疗的前列腺癌患者。
- 骨盆骨(L3/L4交界至坐骨结节)被勾画并计算剂量,剂量按α/β=10转换为2 Gy等效剂量。
- 探索性分析建议按受照体积二分:低体积暴露(LVE)≤1000 cc与高体积暴露(HVE)>1000 cc。
- 采用非参数核回归评估时间、剂量和雄激素剥夺治疗对血红蛋白值的影响。
- 对计划进行重新优化以评估调整显著剂量水平的可行性。
主要发现
- 中位基线血红蛋白为14.9 g/dL(四分位距14.1-15.6)。
- 骨盆骨髓接受≥15 Gy的HVE患者第90天预测血红蛋白为12.8 g/dL(95%CI 12.4-13.3),显著低于LVE患者的14.5 g/dL(95%CI 14.0-14.9)(P<.05)。
- 归一化起始血红蛋白水平后,HVE患者第90天预测血红蛋白仍显著低于LVE患者:86.1%(95%CI 83.2%-89.7%)vs 96.2%(95%CI 92.4%-100%)。
- 重新优化20例接受15 Gy骨髓体积高的计划,接受15 Gy的骨髓体积均值从1422 cc降至997 cc,未损害其他危及器官或靶区覆盖。
关键数值与推荐
- 探索性分析建议将骨盆骨髓受照体积二分:低体积暴露为≤1000 cc,高体积暴露为>1000 cc。
- 剂量按α/β=10转换为2 Gy等效剂量。
- 骨盆骨髓接受≥15 Gy体积>1000 cc者第90天预测血红蛋白显著低于≤1000 cc者(12.8 g/dL vs 14.5 g/dL,P<.05)。
- 归一化后HVE组第90天预测血红蛋白86.1%(95%CI 83.2%-89.7%)显著低于LVE组96.2%(95%CI 92.4%-100%)。
- 作者认为该剂量约束可考虑用于限制前列腺癌患者急性骨髓毒性。
临床怎么用
- 作者认为该剂量约束可考虑用于限制前列腺癌患者急性骨髓毒性。
- 重新优化计划显示将接受15 Gy的骨髓体积从均值1422 cc降至997 cc可行,且未损害其他危及器官或靶区覆盖。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of this work was to investigate the correlation between dose to pelvic bone marrow and anemia when treating prostate cancer (PC) with definitive radiation. METHODS AND MATERIALS: Patients were selected from a prospective institutional database of patients with PC treated between 2008 and 2021. Pelvic bone (L3/L4 interface through ischial tuberosities) was contoured, and the dose to this structure was calculated. Doses were converted to 2-Gy equivalent doses using an α/β of 10. Exploratory analysis suggested dichotomizing into low-volume exposures of ≤1000 cc (LVE) and high-volume exposures of >1000 cc (HVE). Nonparametric kernel regressions were performed evaluating the effects of time, dose, and androgen deprivation therapy use on hemoglobin (Hgb) values. Reoptimization of plans was performed to evaluate the feasibility of adjusting significant dose levels. RESULTS: A total of 203 patients were included in the final analysis. Median baseline Hgb was 14.9 g/dL (interquartile range, 14.1-15.6). Patients with bone marrow HVE ≥15 Gy were found to have significantly lower predicted Hgb levels compared with those with LVE at day 90: 12.8 g/dL (95% CI, 12.4-13.3) versus 14.5 g/dL (95% CI, 14.0-14.9), respectively (P < .05). When normalizing starting Hgb levels, HVE patients still had significantly lower predicted Hgb levels than LVE at day 90: 86.1% (95% CI, 83.2%-89.7%) versus 96.2% (95% CI, 92.4%-100%), respectively. Reoptimizing 20 plans with high volume of bone marrow receiving 15 Gy resulted in a mean reduction from 1422 cc to 997 cc without compromise of other organs at risk or target coverage. CONCLUSIONS: Patients with >1000 cc of bone marrow receiving ≥15 Gy had significantly lower predicted Hgb levels than those with ≤1000 cc. Reoptimization of plans demonstrated that this dose constraint is achievable without impairing plan quality. This dose constraint can be considered to limit acute marrow toxicity in patients with PC.
引用
- Fenlon JB, Nelson G, Teague KM, et al. A Dosimetric Correlation Between Radiation Dose to Bone and Reduction of Hemoglobin Levels After Radiation Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2023. PMID: 37543235. doi:10.1016/j.ijrobp.2023.07.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。